RXRX in the 13F filings
Recursion Pharmaceuticals Inc · CUSIP 75629V104
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 14 Aug 2024
- latest of these filings; the earliest 25 Jul 2024
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 2 listed it in both
- Shares listed
- 55,397,304
- combined, among listed positions
- Reported value
- $415m
- combined, at the quarter end
Among the 94 comparable managers: 3 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +6,741,939.
Managers listing RXRX in Q2 2024
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| ARK Investment Management LLC | 28,142,918 | $211m | 1.87% | Added | +3,555,357 | 26 Jul 2024 (the filing on sec.gov) |
| Baillie Gifford & Co | 26,589,936 | $199m | 0.16% | Added | +2,522,132 | 25 Jul 2024 (the filing on sec.gov) |
| Woodline Partners LP | 664,450 | $5.0m | under 0.1% | New | new | 14 Aug 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- ARK Investment Management LLCexisting position · 28,142,918 shares now+3,555,357
- Baillie Gifford & Coexisting position · 26,589,936 shares now+2,522,132
- Woodline Partners LPnew position · 664,450 shares now+664,450
Reductions
No reduction among listed positions.
New positions and exits
New (1)
- Woodline Partners LP$5.0m
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2021 | 2 | $763m | n.a. | n.a. |
| Q3 2021 | 2 | $567m | n.a. | n.a. |
| Q4 2021 | 2 | $417m | n.a. | n.a. |
| Q1 2022 | 2 | $178m | n.a. | n.a. |
| Q2 2022 | 2 | $193m | n.a. | n.a. |
| Q3 2022 | 2 | $266m | n.a. | n.a. |
| Q4 2022 | 2 | $215m | n.a. | n.a. |
| Q1 2023 | 2 | $192m | n.a. | n.a. |
| Q2 2023 | 2 | $223m | n.a. | n.a. |
| Q3 2023 | 2 | $240m | n.a. | n.a. |
| Q4 2023 | 2 | $442m | 1 | 1 |
| Q1 2024 | 2 | $485m | 1 | 1 |
| Q2 2024 | 3 | $415m | 3 | 0 |
| Q3 2024 | 3 | $387m | 2 | 1 |
| Q4 2024 | 2 | $387m | 0 | 2 |
| Q1 2025 | 3 | $315m | 2 | 1 |
| Q2 2025 | 2 | $289m | 0 | 2 |
| Q3 2025 | 2 | $281m | 1 | 1 |
| Q4 2025 | 2 | $250m | 18 | 8 |
| Q1 2026 | 2 | $196m | 17 | 12 |
| Q2 2026 | 2 | $238m | 13 | 14 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RXRX and GILD →RXRX and AMGN →RXRX and ARGX →Choose a stock to compare with RXRX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RXRX, latest filings →Back to the 13F Explorer →